Mutual of America Capital Management LLC Has $3.85 Million Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Mutual of America Capital Management LLC cut its position in West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 2.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,724 shares of the medical instruments supplier’s stock after selling 198 shares during the period. Mutual of America Capital Management LLC’s holdings in West Pharmaceutical Services were worth $3,848,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of West Pharmaceutical Services during the fourth quarter worth approximately $300,250,000. Artisan Partners Limited Partnership raised its stake in shares of West Pharmaceutical Services by 23.2% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,961,063 shares of the medical instruments supplier’s stock worth $690,530,000 after buying an additional 369,792 shares during the last quarter. APG Asset Management US Inc. bought a new stake in shares of West Pharmaceutical Services during the fourth quarter worth approximately $88,227,000. TD Asset Management Inc raised its stake in shares of West Pharmaceutical Services by 38.4% during the fourth quarter. TD Asset Management Inc now owns 659,560 shares of the medical instruments supplier’s stock worth $232,244,000 after buying an additional 183,153 shares during the last quarter. Finally, Findlay Park Partners LLP raised its stake in shares of West Pharmaceutical Services by 65.2% during the fourth quarter. Findlay Park Partners LLP now owns 457,306 shares of the medical instruments supplier’s stock worth $161,027,000 after buying an additional 180,415 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the sale, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Silji Abraham sold 1,800 shares of the stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the sale, the senior vice president now owns 2,860 shares of the company’s stock, valued at $946,030.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric Mark Green sold 66,000 shares of the stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the sale, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The disclosure for this sale can be found here. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Trading Up 0.9 %

WST opened at $321.35 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. The company has a market cap of $23.41 billion, a price-to-earnings ratio of 42.39, a price-to-earnings-growth ratio of 5.65 and a beta of 1.00. The firm has a 50 day simple moving average of $335.13 and a 200 day simple moving average of $358.65. West Pharmaceutical Services, Inc. has a fifty-two week low of $310.00 and a fifty-two week high of $415.73.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last issued its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.29 by $0.27. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The firm had revenue of $695.40 million during the quarter, compared to the consensus estimate of $670.62 million. During the same quarter in the prior year, the firm earned $1.98 earnings per share. The business’s quarterly revenue was down 3.0% on a year-over-year basis. On average, sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 7.76 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.25%. The ex-dividend date of this dividend is Wednesday, July 31st. West Pharmaceutical Services’s payout ratio is presently 10.55%.

West Pharmaceutical Services Company Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Further Reading

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.